ACAD (STOCKS)
Acadia Pharmaceuticals Inc.
$21.260000
+0.170000 (+0.81%)
Prev close: $21.090000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Catherine Owen Adams
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3,642.19M
- Employees
- 654
- P/E (TTM)
- 9.60
- P/B (TTM)
- 2.89
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $1.10B |
| Benefits Costs and Expenses | $980.14M |
| Cost Of Revenue | $93.40M |
| Costs And Expenses | $1.01B |
| Gross Profit | $1.00B |
| Operating Expenses | $920.95M |
| Selling, General, and Administrative Expenses | $593.54M |
| Research and Development | $327.41M |
| Operating Income/Loss | $80.91M |
| Income/Loss From Continuing Operations After Tax | $375.65M |
| Income/Loss From Continuing Operations Before Tax | $115.11M |
| Income Tax Expense/Benefit | -$260.54M |
| Net Income/Loss | $375.65M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $375.65M |
| Net Income/Loss Available To Common Stockholders, Basic | $375.65M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $2.23 |
| Diluted Earnings Per Share | $2.21 |
| Basic Average Shares | 507,699,000 |
| Diluted Average Shares | 512,800,000 |
| Assets | $1.61B |
| Current Assets | $1.10B |
| Inventory | $112.29M |
| Prepaid Expenses | $64.60M |
| Other Current Assets | $919.12M |
| Noncurrent Assets | $509.21M |
| Fixed Assets | $14.65M |
| Other Non-current Assets | $494.56M |
| Liabilities | $357.16M |
| Current Liabilities | $305.52M |
| Accounts Payable | $12.25M |
| Wages | $31.43M |
| Other Current Liabilities | $261.85M |
| Noncurrent Liabilities | $51.64M |
| Equity | $1.25B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.25B |
| Liabilities And Equity | $1.61B |
| Net Cash Flow From Operating Activities | $123.49M |
| Net Cash Flow From Operating Activities, Continuing | $123.49M |
| Net Cash Flow From Investing Activities | -$112.23M |
| Net Cash Flow From Investing Activities, Continuing | -$112.23M |
| Net Cash Flow From Financing Activities | $52.28M |
| Net Cash Flow From Financing Activities, Continuing | $52.28M |
| Net Cash Flow | $63.54M |
| Net Cash Flow, Continuing | $63.54M |
| Comprehensive Income/Loss | $374.65M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $374.65M |
| Other Comprehensive Income/Loss | $97.45M |